June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Subretinal Pneumatic Displacement without Tissue Plasminogen Activator for Submacular Hemorrhage: One-year Outcomes.
Author Affiliations & Notes
  • Marwan Abdulaal
    Ophthalmology, Case Western Reserve University, Cleveland, Ohio, United States
  • Jacobi Robertson
    University of Wisconsin-Madison, Madison, Wisconsin, United States
  • Madison T Moore
    University System of Maryland, Adelphi, Maryland, United States
  • Joseph M Coney
    Ophthalmology, Case Western Reserve University, Cleveland, Ohio, United States
  • Footnotes
    Commercial Relationships   Marwan Abdulaal, None; Jacobi Robertson, None; Madison Moore, None; Joseph Coney, None
  • Footnotes
    Support  NONE
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 3663. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Marwan Abdulaal, Jacobi Robertson, Madison T Moore, Joseph M Coney; Subretinal Pneumatic Displacement without Tissue Plasminogen Activator for Submacular Hemorrhage: One-year Outcomes.. Invest. Ophthalmol. Vis. Sci. 2021;62(8):3663.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the outcome of pneumatic displacement of submacular hemorrhage with Subretinal Air and without tissue plasminogen activator (TPA) for thick submacular hemorrhages (SMH).

Methods : Retrospective analysis of patients with submacular hemorrhage managed surgically via pneumatic displacement without TPA from 2015 and 2020. Surgical intervention across all doctors included subretinal Balanced Saline Solution (BSS) infusion with subretinal sterile air, and intraocular gas tamponade with and without postsurgical anti-vascular endothelial growth factor (VEGF) injection. 24 patients with SMH and at least 8 months of follow up were identified. All medical records and color fundus photographs were reviewed for data collection. The primary outcome measure was best-corrected visual acuity (BCVA) 12 months after treatment. Secondary outcome measures included central retinal thickness (CRT), recurrence rate, and complications.

Results : Patients had a mean age of 81 ± 8.6 years. Wet age-related macular degeneration was the most common etiology associated with thick SMH (92%). Complete blood displacement was observed by final follow up in 92% of the cases and none in 8.0%. Mean logMAR BCVA improved from 1.2 ± 0.27 (20/320 at baseline) to 0.9 ± 0.42 (Snellen 20/160; p = 0.001) at final follow-up. 63% of the patients gained at least 2 lines by the 12 months of follow up. Mean central retinal thickness was also improved from 569µ ± 220 at baseline to 252µ ± 63 by 12 months of follow up (P<0.001). Early postoperative complications included vitreous hemorrhage in two cases and retinal detachment in 2 patients. It was noted that 11 patients (46%) developed subretinal fibrosis at 12 months of follow up.

Conclusions : Vitrectomy with subretinal BSS injection and pneumatic displacement without TPA was found to be effective for displacement of thick submacular hemorrhage with improvement in visual acuity

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×